Investigating how certain molecules affect the risk of pulmonary arterial hypertension
Official title: Eicosanoid Pathways Underlying Disease Risk in Pulmonary Arterial Hypertension
Funded at University of California, San Diego · NIH-11001975 · Data updated 2026-11-12
This study is looking at how changes in metabolism and certain markers in the body affect pulmonary arterial hypertension (PAH), with the goal of finding better ways to treat this serious condition and help patients feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $174,096 |
| NIH project number | 5K08HL166950-02 |
| Project ID | NIH-11001975 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension or those at risk for developing this condition.
✕Less likely to help
Patients with other forms of pulmonary hypertension unrelated to the mechanisms being studied may not benefit from this research.
What this research studies
This research focuses on understanding the role of metabolic changes and specific molecular markers in the progression of pulmonary arterial hypertension (PAH). The approach involves both human studies and experimental models to identify potential biomarkers that could lead to better treatment options. The research aims to enhance the knowledge of how endothelial dysfunction contributes to PAH, which is a serious condition that can lead to heart failure if not managed properly. By developing sensitive methods to detect these biomarkers, the research seeks to improve patient outcomes through more personalized treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for patients with pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for other cardiovascular diseases, suggesting that this approach could yield valuable insights for pulmonary arterial hypertension as well.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Alotaibi, Mona a — University of California, San Diego
- Study coordinator: Alotaibi, Mona a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.